Heart Failure and Aortic Stenosis Transcriptome
Key facts
- Where
- Milan és San Donato Milanese, OlaszországSee the 2 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 40 and 75 years old?
Forrás: NCT03268135: ki vehet részt
Where in Olaszország
- Ospedale San RaffaeleMilan, OlaszországTaking people
- IRCCS Policlinico San DonatoSan Donato Milanese, OlaszországTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- IRCCS Policlinico S. Donato
- Trial code
- NCT03268135
- Record updated
- 2026. november 4.
- Original description
This study is aimed to investigate the global transcriptome in order to determine the expression profile of messenger RNAs (mRNAs), as well as long noncoding- (lncRNAs) and micro noncoding-RNAs (miRNAs) in heart failure (HF) and in aortic stenosis (AS). The aim is to clarify their role in cardiac disease pathogenesis, as well as their potential as biomarkers. To this purpose, both tissue and blood specimens will be collected and patients will be compared to individuals not affected by cardiovascular diseases.Read full original descriptionShow less
Study of the Transcriptomic Alterations in Heart Failure and Aortic Stenosis
This study is aimed to investigate the global transcriptome in order to determine the expression profile of messenger RNAs (mRNAs), as well as long noncoding- (lncRNAs) and micro noncoding-RNAs (miRNAs) in heart failure (HF) and in aortic stenosis (AS). The aim is to clarify their role in cardiac disease pathogenesis, as well as their potential as biomarkers. To this purpose, both tissue and blood specimens will be collected and patients will be compared to individuals not affected by cardiovascular diseases.
Inclusion: Non end-stage heart failure; left ventricle restoration surgery (SVR); End Systolic Volume Index (ESVI) >35 ml/m2; Ejection Fraction (EF)<40%; previous transmural anterior myocardial infarction (MI); age: 40-75; End-stage heart failure; left ventricle assisted device (LVAD) surgery; age: 40-75; Ejection Fraction (EF) <25%; End Systolic Volume Index (ESVI)≥60 ml/m2; Aortic Stenosis; aortic valve replacement; intracardial pressure difference >40 mmHg; septal diameter ≥1.3 cm.
Exclusion: End-stage heart failure; EF>25%; Time from MI unknown; Pregnancy; Other genetic diseases; Neoplasms; Collagenopathies; Chemo/radiotherapy; Prolonged use of corticosteroids; Infections; Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV) (not vaccination) and Hepatitis C Virus (HCV) positive; Aortic Stenosis; coronaropathies; Pregnancy; Other genetic diseases; Neoplasms; Collagenopathies; Chemo/radiotherapy; Prolonged use of corticosteroids; Infections; Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV) (not vaccination) and Hepatitis C Virus (HCV) positive; Non end-stage heart failure; End Systolic Volume Index (ESVI)<35 ml/m2; Ejection Fraction (EF)>40%; Time from MI unknown; Pregnancy; Other genetic diseases; Neoplasms; Collagenopathies; Chemo/radiotherapy; Prolonged use of corticosteroids; Infections; Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV) (not vaccination) and Hepatitis C Virus (HCV) positive.